Pulse Biosciences initiated with an Outperform at Mizuho

Mizuho initiated coverage of Pulse Biosciences (PLSE) with an Outperform rating and $25 price target The firm says its “bullish” physician feedback supports rapid adoption of the company’s nanosecond pulsed field ablation technology post FDA clearance. It sees potential for the shares to re-rate higher under a scenario where the 12-month European early feasibility data shows higher efficacy duration versus competing solutions.